Attorney's Docket No.: 01997-273003 / MIT Case 7772 DI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Moungi G. Bawendi et al.

Art Unit : 1641

OCT 2 5 2002

Serial No.: 09/832,959

Examiner: Christopher L. Chin

TECH CENTER 1600/2900

Filed

April 12, 2001

Title : BIOLOGICAL APPLICATIONS OF QUANTUM DOTS

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed September 23, 2002 ("Office Action"), Applicants elect the invention of Group II (claims 69-77) drawn to a method of detecting biological moieties. The election is made with traverse.

Applicants respectfully request that the invention of Group I (claims 46-47, 49-68 and 78) drawn to a method of detecting interaction between a composition and a biological mojety be combined with the invention of Group II. The Examiner indicates at page 3 of the Office Action that the "inventions are not disclosed as capable of use together because they are directed to two different method [sic] with different method steps and use different reagent [sic] and thus have different modes of operation to produce different effects." Applicants respectfully disagree. Both independent claim 46 (Group I) and independent claim 69 (Group II) relate to a method of using compound and a semiconductor nanocrystal associated with the compound. The reagent is not different. Both claims include allowing a sample to interact with the composition and monitoring or detecting an interaction, which are similar method steps. Thus, the claims of Group I and the claims of Group II should be searched together. Applicants respectfully request that Group II and Group I be combined and examined together.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

12.12°

Date: 10-23-02

Harold H. Fox

Reg. No. 41,498

Fish & Richardson P.C. 1425 K Street, N.W.

Washington, DC 20005-3500 Telephone: (202) 783-5070 Facsimile: (202) 783-2331

40125623.doc